Biggest News Aggregation in the World
📰 Early Access Program News

Page 14 - Early Access Program News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Early Access Program. Real-time updates on events, politics, business and more.

Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration

– Zeno granted BTD for the treatment of NRG1+ non-small cell lung cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 05, 2023 -- Merus N.V. , a clinical-stage oncology company...
United States United Kingdom Drug Administration Exchange Commission Early Access Program American Society Of Clinical Oncology Annual Meetings

Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, to...
United States United Kingdom Early Access Program Drug Administration Eu Press Exchange Commission

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer - Merus (NASDAQ:MRUS)

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics®
United States United Kingdom Drug Administration American Society Of Clinical Oncology Annual Meetings Exchange Commission Corporate Communications

AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of Nebraska for Phase 2 study of Ampligen® for... | June 12, 2023
United States South Africa University Of Nebraska Medical Center South African Thomask Equels Kelsey Klute

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science